Insulet (PODD) Stock Price, News & Analysis

Company Overview

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps.

Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

Insulet serves customers in the United States and international markets. In addition to its diabetes products, the company develops drug-delivery technologies for pharmaceutical and biotechnology partners.

Key Stats

• Today's Range: $145.31 to $153.79
• 50-Day Range: $130.56 to $165.02
• 52-Week Range: $126.40 to $354.88
• Volume: 1.59 million shs
• Average Volume: 1.35 million shs
• Market Capitalization: $10.58 billion
• P/E Ratio: 22.55
• Dividend Yield: N/A
• Price Target: $185.67
• Consensus Rating: Hold

Insulet Stock Analysis - MarketRank™

Insulet scored higher than 85% of companies evaluated by MarketBeat, and ranked 40th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Insulet has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on no strong buy ratings, 12 buy ratings, 12 hold ratings, and 1 sell rating.

Upside Potential

Insulet has a consensus price target of $185.67, representing about 21.8% upside from its current price of $152.48.

Amount of Analyst Coverage

Insulet has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 18.64%

Earnings Growth

Earnings for Insulet are expected to grow by 18.64% in the coming year, from $6.76 to $8.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Insulet is 24.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Insulet is 24.83, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.60.

Price to Earnings Growth Ratio

Insulet has a PEG Ratio of 1.14. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Insulet has a P/B Ratio of 6.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.71% of the float of Insulet has been sold short.

Short Interest Ratio / Days to Cover

Insulet has a short interest ratio ("days to cover") of 4.25.

Change versus previous month

Short interest in Insulet has recently decreased by 5.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Insulet does not currently pay a dividend.

Dividend Growth

Insulet does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.87

News Sentiment

Insulet has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Insulet this week, compared to 9 articles on an average week.

Search Interest

Only 11 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Insulet insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.36% of the stock of Insulet is held by insiders.

Percentage Held by Institutions

Insulet has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/04/2026
• Today: 11/13/2026
• Jefferies Global Healthcare Conference: 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:PODD
• CIK: 1145197
• Web: www.insulet.com
• Phone: (978) 600-7000
• Fax: 978-600-0120
• Employees: 5,400
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Insulet: $185.67
• High Price Target: $235.00
• Low Price Target: $144.00
• Potential Upside/Downside: +21.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.14
• Trailing P/E Ratio: 24.83
• Forward P/E Ratio: 19.01
• P/E Growth: 1.14
• Net Income: $247.10 million
• Net Margins: 13.44%
• Pretax Margin: 17.21%
• Return on Equity: 31.76%
• Return on Assets: 14.48%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 2.51
• Quick Ratio: 1.83

Sales & Book Value

• Annual Sales: $2.71 billion
• Price / Sales: 3.91
• Cash Flow: $6.43 per share
• Price / Cash Flow: 23.73
• Book Value: $22.76 per share
• Price / Book: 6.70

Miscellaneous

• Outstanding Shares: 69,370,000
• Free Float: 69,121,000
• Market Cap: $10.58 billion
• Optionable: Optionable
• Beta: 1.06